NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Creative Bioarray's New In Vitro Metabolism Assay Kits for Drug Testing
TL;DR
Creative Bioarray's new metabolic assay kits give pharmaceutical companies a competitive edge by accelerating drug development with precise, reproducible data.
Creative Bioarray's kits utilize CYP450 and UGT enzyme systems with customizable protocols for detailed analysis of Phase I and II metabolic processes.
These innovative kits help researchers develop effective treatments faster, advancing medical science and improving healthcare outcomes for people worldwide.
Creative Bioarray's metabolic kits reveal drug behavior through biochemical pathways, offering a fascinating glimpse into how medications interact with the body.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Bioarray has launched a new suite of personalized, high-efficiency in vitro metabolic assay kits and reagents designed to support researchers and pharmaceutical companies in drug testing.
Drug metabolism plays a crucial role in early drug development stages, and these kits help researchers study metabolic pathways, assess compound metabolic stability, evaluate drug interactions, and identify metabolic pathways with unprecedented ease and precision.
The kits are built upon widely used cytochrome P450 (CYP450) and UDP-glucuronyl transferase (UGT) enzyme systems, enabling researchers to gain insights into Phase I and Phase II metabolic processes through customizable protocols.
The kits offer comprehensive support for drug testing with customizable protocols, detailed assessment of compound-metabolic enzyme interactions, scalability for diverse throughput requirements, and generation of quantitative, robust, and reproducible data.
The kits are designed for researchers and pharmaceutical companies, making them suitable for both small laboratories and large-scale industrial applications in the biopharmaceutical field.
The kits focus on Phase I and II metabolic reactions, including oxidation, reduction, hydrolysis, conjugation, and the formation of more readily excreted polar metabolites.
Creative Bioarray offers specialized services including custom assays for drug interactions and metabolite identification, providing comprehensive support throughout the entire drug development process.
By using these products, researchers can significantly accelerate drug development and ensure their leading position in the highly competitive biopharmaceutical field through improved efficiency and reliable data generation.
The announcement was made on November 30, 2025, as part of Creative Bioarray's ongoing commitment to providing innovative solutions for life science research.
More information about Creative Bioarray's in vitro metabolic assay kits can be found on their website.
Curated from 24-7 Press Release
